Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological diagnosis of myxoid / round cell liposarcoma (MRCL) and availability of pathology specimens for central review and pharmacogenomic studies~* Clinical evidence of locally advanced (Stage III), non-metastatic tumor, including locally recurring disease after initial surgery~* Measurable disease (by Response Evaluation Criteria In Solid Tumors \[RECIST\])~* No prior chemotherapy or radiation (except for adjuvant post-operative radiotherapy)~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2~Exclusion Criteria:~* Known hypersensitivity to any of the components of the trabectedin intravenous (iv) formulation or dexamethasone~* Pregnant or lactating women and women of reproductive potential who are not using effective contraceptive methods~* History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 5 years or longer~* Known distant metastases~* Other serious illnesses such as congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trabectedin (Type: EXPERIMENTAL): Trabectedin at a dose of 1.5 milligram per meter square (mg/m\^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).